Akero Therapeutics Inc
AKRO54.650USD
0.000
Market hours （ET）Quotes delayed by 15 min
4.38BMarket Cap
LossP/E TTM
More Details of Akero Therapeutics Inc Company
Akero Therapeutics, Inc. is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Efruxifermin (EFX), its lead product candidate for MASH, is being evaluated in three ongoing Phase 3 studies: SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, and SYNCHRONY Real-World in patients with MASH (F1-F4). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.
Akero Therapeutics Inc Info
Ticker SymbolAKRO
Company nameAkero Therapeutics Inc
IPO dateJun 20, 2019
CEOCheng (Andrew)
Number of employees63
Security typeOrdinary Share
Fiscal year-endJun 20
Address601 Gateway Boulevard, Suite 350
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16504876488
Websitehttps://akerotx.com/
Ticker SymbolAKRO
IPO dateJun 20, 2019
CEOCheng (Andrew)
Company Executives of Akero Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Christina Tartaglia
Ms. Christina Tartaglia
Investor Relations
Investor Relations
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Christina Tartaglia
Ms. Christina Tartaglia
Investor Relations
Investor Relations
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Janus Henderson Investors
7.63%
General Atlantic LLC
6.97%
RTW Investments L.P.
6.65%
BlackRock Institutional Trust Company, N.A.
6.08%
The Vanguard Group, Inc.
5.48%
Other
67.19%
Shareholders
Shareholders
Proportion
Janus Henderson Investors
7.63%
General Atlantic LLC
6.97%
RTW Investments L.P.
6.65%
BlackRock Institutional Trust Company, N.A.
6.08%
The Vanguard Group, Inc.
5.48%
Other
67.19%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
47.13%
Investment Advisor
30.65%
Hedge Fund
18.32%
Private Equity
9.73%
Research Firm
2.95%
Venture Capital
2.56%
Individual Investor
1.08%
Foundation
0.40%
Pension Fund
0.33%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
504
92.63M
123.44%
-26.38K
2025Q3
532
92.72M
128.44%
-619.25K
2025Q2
513
93.19M
122.60%
+5.80M
2025Q1
481
87.41M
107.62%
+1.72M
2024Q4
438
74.28M
124.07%
+570.22K
2024Q3
432
73.67M
126.17%
-695.38K
2024Q2
416
72.42M
128.65%
-3.01M
2024Q1
408
73.91M
107.89%
+1.88M
2023Q4
389
59.72M
117.03%
+1.94M
2023Q3
376
57.78M
113.32%
+701.00K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Janus Henderson Investors
6.74M
8.42%
-330.09K
-4.67%
Jun 30, 2025
General Atlantic LLC
5.73M
7.17%
+500.00K
+9.55%
Jun 30, 2025
RTW Investments L.P.
5.48M
6.85%
-1.94M
-26.17%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.06M
6.33%
-421.07K
-7.68%
Jun 30, 2025
The Vanguard Group, Inc.
4.52M
5.65%
+297.51K
+7.05%
Jun 30, 2025
Wellington Management Company, LLP
3.41M
4.26%
-2.53M
-42.56%
Jun 30, 2025
Deep Track Capital LP
3.04M
3.8%
-167.67K
-5.22%
Jun 30, 2025
Avoro Capital Advisors LLC
3.50M
4.38%
+3.50M
--
Jun 30, 2025
T. Rowe Price Associates, Inc.
4.42M
5.53%
-310.43K
-6.56%
Jun 30, 2025
State Street Investment Management (US)
2.75M
3.43%
+250.82K
+10.05%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Simplify Propel Opportunities ETF
11.66%
ProShares Merger ETF
2.71%
State Street SPDR S&P Biotech ETF
1.78%
ALPS Medical Breakthroughs ETF
1.75%
AltShares Merger Arbitrage ETF
1.63%
Direxion Daily S&P Biotech Bull 3X Shares
1.1%
ProShares Ultra Nasdaq Biotechnology
0.43%
Invesco Nasdaq Biotechnology ETF
0.42%
iShares Biotechnology ETF
0.34%
Pacer WealthShield ETF
0.28%
View more
Simplify Propel Opportunities ETF
Proportion11.66%
ProShares Merger ETF
Proportion2.71%
State Street SPDR S&P Biotech ETF
Proportion1.78%
ALPS Medical Breakthroughs ETF
Proportion1.75%
AltShares Merger Arbitrage ETF
Proportion1.63%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion1.1%
ProShares Ultra Nasdaq Biotechnology
Proportion0.43%
Invesco Nasdaq Biotechnology ETF
Proportion0.42%
iShares Biotechnology ETF
Proportion0.34%
Pacer WealthShield ETF
Proportion0.28%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Akero Therapeutics Inc?
The top five shareholders of Akero Therapeutics Inc are:
Janus Henderson Investors holds 6.74M shares, accounting for 8.42% of the total shares.
General Atlantic LLC holds 5.73M shares, accounting for 7.17% of the total shares.
RTW Investments L.P. holds 5.48M shares, accounting for 6.85% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.06M shares, accounting for 6.33% of the total shares.
The Vanguard Group, Inc. holds 4.52M shares, accounting for 5.65% of the total shares.
Janus Henderson Investors holds 6.74M shares, accounting for 8.42% of the total shares.
General Atlantic LLC holds 5.73M shares, accounting for 7.17% of the total shares.
RTW Investments L.P. holds 5.48M shares, accounting for 6.85% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.06M shares, accounting for 6.33% of the total shares.
The Vanguard Group, Inc. holds 4.52M shares, accounting for 5.65% of the total shares.
What are the top three shareholder types of Akero Therapeutics Inc?
The top three shareholder types of Akero Therapeutics Inc are:
Janus Henderson Investors
General Atlantic LLC
RTW Investments L.P.
Janus Henderson Investors
General Atlantic LLC
RTW Investments L.P.
How many institutions hold shares of Akero Therapeutics Inc (AKRO)?
As of 2025Q4, 504 institutions hold shares of Akero Therapeutics Inc, with a combined market value of approximately 92.63M, accounting for 123.44% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -5.00%.
What is the biggest source of revenue for Akero Therapeutics Inc?
In --, the -- business generated the highest revenue for Akero Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
